Mit - Index

Mit - UVK_Sinfo_2008_09_št.13 - Index

All of the above-mentioned remarkable features of CIM monoliths
have been confirmed by all the main scientific opinion leaders.
The big industries and other scientists and researchers eagerly
follow them.
The excellence of the Slovene company was seen in 2001 in the
signing of a contract with the multinational company Boehringer
Ingelheim, one of the greatest biopharmaceutical companies in
the world. Together they developed a purification process for
plasmid DNA molecules (genetic medicines), which brought
them a prestigious 2004 Frost & Sullivan Technology Leadership
Award. Credit for the award goes mainly to the CIM technology
developed by the Slovene company. In addition, BIA Separations
have developed a partnership in consortiums entrusted by the
European Commission to develop a vaccine for bird flu and flu
(Fluvacc). Given the nature of the company’s work, the quality
is of extreme importance − it must suit the requirements of
pharmaceutical regulations. The company has successfully
passed the Good Laboratory Practice (GLP) and Food and Drug
Administration (FDA) tests and in December 2003 acquired a
quality certificate ISO 9001:2000.
mONOLITh SUmmER SymPOSIUm 2008
(mSS2008) IN ThE TOwN Of PORTOROŽ
One hundred and twenty researchers and scientists from
academic and industry circles gathered at this year’s third
symposium. They came from more than twenty-five countries
and cooperated in discussions with leading figures in the field
of monolith technology, presenting unique achievements in
biotechnological development and pharmacy. A young Slovene
researcher received the MSS Young Researchers Corner Best
Presentation Award.
mAGNIfICENT CELEBRATION Of ThE
TENTh ANNIVERSARy IN zEmONO
mANSION
The company, with its registered office in neighbouring
Klagenfurt and a branch office in the United States of America,
as well as more than twenty distributors around the world, is
celebrating its tenth anniversary this year. The anniversary will
27
ouRexCellenCe
mark the beginning of the construction of a new production
line and research laboratories in the Vipava valley, in the town of
AjdovšËina. The company has set its goals high, but considering
their experience, they are all realistically reachable. Besides their
mid-term goal to reach the technological exchange in Great Britain
or Switzerland, the company wishes to become a world leader in
innovative liquid separation biochromatography by combining the
power of their short monolithic column technology, experience
in the development and validation of analytical methods and
their accumulated knowledge in biomolecule purification
processes to meet the diversified needs of their pharmaceutical
and biotechnology customers.
BIA SEPARATIONS IS DEVOTED TO ITS
CUSTOmERS
Along with offering purification solutions and quality products,
exceptional customer service is the most important aspect of their
business in the care for their business reputation. As they are
introducing new technology to the market, they are aware of the
need to provide the most accurate and honest answers to their
customers in order to build long-lasting business relationships.
Therefore, they are committed to handling all customer inquiries
on the spot, or to providing a feasible answer within the following
24 hours.
13 sinfo